Vitruvian Partners

Canaccord Genuity Advises Vitruvian Partners on its $637 Million Investment in Leading Healthcare DSP DeepIntent to Accelerate AI-Driven Transformation of Healthcare Marketing

Funding will be a catalyst for DeepIntent’s next phase of growth, product development, and industry leadership – empowering clients with smarter marketing solutions

Canaccord Genuity has advised Vitruvian Partners, a global investment firm specializing in high-growth technology leaders, on its $637 million investment in DeepIntent, Inc., the leading healthcare demand-side platform (DSP). The investment will accelerate DeepIntent’s next phase of expansion and product innovation – enhancing its platform with new generative AI capabilities and integrations that improve patient outcomes through the use of real-world data, real-time advertising, and data science. The company’s continued evolution will build on its proprietary software platform, powered by Health Intelligence™, which unifies media, clinical data, and AI to drive more meaningful engagement between life sciences brands, healthcare providers (HCPs), and patients.

DeepIntent’s DSP technology has been purpose-built to help marketers plan, activate, and optimize data-driven campaigns with speed and precision. Trusted by the world’s top healthcare brands and their agencies, the company uniquely unites media, identity, and real-world clinical data to power privacy-safe, omnichannel marketing across every screen. Backed by patented technology and proven outcomes, DeepIntent’s platform delivers measurable audience quality and script lift at scale. 

Since its founding in 2016, DeepIntent has led the digital transformation of healthcare marketing with a category-defining platform that connects brands with healthcare providers (HCPs), patients, and health consumers across the United States. Today, DeepIntent powers campaigns for hundreds of brands –  including 19 of the top 20 global life sciences companies and their agencies – by serving as the connective software that enables high-impact engagement with HCPs and patients across digital channels, including streaming TV, podcasts, point-of-care media, and more. Data-driven digital advertising has already transformed its clients’ ability to bring innovative therapeutics to market faster and more efficiently, and recent advancements in generative AI and real-world data will enable DeepIntent to offer a new level of precision – delivering highly personalized brand experiences by unifying the industry’s most comprehensive data and premium media within a single, integrated platform. 

Vitruvian Partners is a global growth-focused investor with offices across London, Miami, San Francisco, Stockholm, Munich, Madrid, Luxembourg, Mumbai, Singapore, and Shanghai. The firm focuses on dynamic situations characterized by rapid growth and change across asset-light industries. Vitruvian has more than $20 billion of active funds that have backed many global winners and leaders in their sectors, including CRF Health, Medison Pharma, Just Eat, EasyPark, Skyscanner, Wise, Global-e, CFC, and Darktrace.

DeepIntent sits at the forefront of powerful structural growth drivers, including the rise of personalized, patient-centered healthcare and the growing availability of data and machine learning to enable more meaningful connections with relevant audiences. With the backing of Vitruvian Partners, the company plans to expand and scale its offerings rapidly, while continuing to build out its marketplace of strategic data and media partners. Clients will gain early and enhanced access to next-generation Health Intelligence™ – helping their brands reach verified HCP and patient audiences with greater precision, improve campaign performance dynamically, and stand out in an increasingly competitive healthcare landscape.

The transaction represents a new chapter for DeepIntent, with Vitruvian acquiring a majority interest in the company. The company will continue to operate independently under the leadership of its founder and CEO, Chris Paquette. As part of the transaction, DeepIntent’s board of directors will be reconstituted to include a select group of industry leaders and domain experts, bringing deep experience in healthcare, technology, and data-driven marketing to help guide the company’s next phase of growth.